Market Eyes LiveHims & Hers Health, Inc. (HIMS) Stock Rating & Analysis
MELANY's data-driven read on Hims & Hers Health, Inc. · Services-Offices & Clinics of Doctors of Medicine.
Hims & Hers, launched in 2017, is a telehealth platform connecting patients with healthcare providers for specialties such as erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. With more than 2 million subscribers, it operates in all 50 states and some European markets such as the UK.
Why HIMS scores 49/100
MELANY scores Hims & Hers Health, Inc. 49/100 by weighing eight factors. Here is how HIMS breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 73%
Direction and relative strength of the recent share-price trend.
- Price +18.3% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Institutional net buying +4.4%
Near-term events that could move the stock.
- Earnings in 31 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for HIMS
- High debt-to-equity ratio 2.5x, rate-sensitive balance sheet
- Operating margin -8%, cash-burn business, dependent on capital markets
- Short interest 34% of float, high volatility risk on news
- High beta 2.3, amplifies market drawdowns 1.8x+ in selloffs
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Hims & Hers Health, Inc. sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 64/100 for strength. Theme strength feeds HIMS's momentum and catalyst factors above.
HIMS trade plan (members only)
MELANY has a full position plan for Hims & Hers Health, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates HIMS
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Hims & Hers Health, Inc.'s 49/100 reflects speculative factor weighting for its profile. Long-horizon position framework with quarterly score-based check-ins.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about HIMS
Is Hims & Hers Health, Inc. (HIMS) a buy?
As of 2026-07-11, MELANY rates Hims & Hers Health, Inc. Promising with a composite score of 49/100. This is an algorithmic, data-driven rating built from eight factors, not personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Hims & Hers Health, Inc.'s MELANY score?
Hims & Hers Health, Inc. (HIMS) has a MELANY composite score of 49/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the HIMS stock rating calculated?
MELANY scores HIMS from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
How current is this HIMS rating?
The rating on this page reflects MELANY's read as of 2026-07-11. The price shown updates live; the composite score refreshes continuously as new data arrives.
HIMS's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.